SEKISUI Diagnostics, a US-based medical diagnostics solutions provider, has unveiled its OSOM Covid-19 antigen home test to diagnose Covid-19 at home.
OSOM Covid-19 antigen home test is a lateral flow immunoassay tool. It is designed for the qualitative identification of SARS-CoV-2 virus nucleocapsid protein antigen.
According to SEKISUI Diagnostics, the test is created in the US and maintained by a technical support staff of medical technologists and professionals, just like other OSOM rapid tests.
SEKISUI Diagnostics Clinical Research & Marketing and Client Services VP Erica Blight said: “We are excited to be able to provide consumers with more tools to help diagnose Covid-19 in a fast, easy-to-use format that can be purchased over the counter.
“This supports our goal of bringing diagnostics to where they are needed most, which in this case is at home, so people do not have to travel to medical facilities and can treat or quarantine quickly.”
Through a collection of point-of-care tests sold under the OSOM and Acucy brands, the company is a supplier of numerous rapid testing solutions to the professional market.
These simple, effective tests have offered flexibility to healthcare practitioners and they are now being introduced to the market for home testing, the medical diagnostics solutions provider claimed.
The test is not yet cleared or approved by the US Food and Drug Administration (FDA) but has been authorised by FDA under a conditional Emergency Use Authorisation (EUA).
OSOM Covid-19 antigen home test is intended only for the detection of proteins from SARS-CoV-2, not for any other pathogens or viruses.
SEKISUI Diagnostics president & CEO Bob Schruender said: “Our entrance into the home testing market is another way we are providing solutions to enhance life with science to improve the health of all people.
“We understand home testing is a valuable tool and becoming more accepted and necessary, especially when we are experiencing significant waves of respiratory infections as we have seen in previous seasons.”
